TargetMol

AD 8717

Product Code:
 
TAR-T29635
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29635-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
0
CAS:
181821-99-8
Formula:
C22H19Cl2N5O
Molecular Weight:
450.41
Purity:
0.98
SMILES:
O=C(C1=NNC2=C1C=CC=C2)N[C@H]3CN(CC4=CC=CC(C)=C4)CCN(C)C3.[H]Cl.[H]Cl

References

1. Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2017 Feb 14;116(4):464-471. doi: 10.1038/bjc.2016.436. Epub 2017 Jan 12. PubMed PMID: 28081543; PubMed Central PMCID: PMC5318973. 2. Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Nagai Y, Asami C, Kitagawa Y. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016 Nov 22;115(11):1328-1334. doi: 10.1038/bjc.2016.350. Epub 2016 Nov 3. PubMed PMID: 27811857; PubMed Central PMCID: PMC5129815. 3. Hasegawa Y, Iuchi T, Sakaida T, Yokoi S, Kawasaki K. The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. J Clin Neurosci. 2016 Sep;31:67-71. doi: 10.1016/j.jocn.2015.12.033. Epub 2016 Jul 16. PubMed PMID: 27430412. 4. Kopajtich R, Murayama K, Janecke AR, et al. Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy. Am J Hum Genet. 2016 Aug 4;99(2):414-22. doi: 10.1016/j.ajhg.2016.05.027. Epub 2016 Jul 14. PubMed PMID: 27426735; PubMed Central PMCID: PMC4974065.